65 related articles for article (PubMed ID: 18996486)
1. Expression and purification of human full-length N Oct-3, a transcription factor involved in melanoma growth.
Cabos-Siguier B; Steunou AL; Joseph G; Alazard R; Ducoux-Petit M; Nieto L; Monsarrat B; Erard M; Clottes E
Protein Expr Purif; 2009 Mar; 64(1):39-46. PubMed ID: 18996486
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of phosphorylation on DNA binding properties of N Oct-3 are dictated by protein/DNA complex structures.
Nieto L; Joseph G; Stella A; Henri P; Burlet-Schiltz O; Monsarrat B; Clottes E; Erard M
J Mol Biol; 2007 Jul; 370(4):687-700. PubMed ID: 17543985
[TBL] [Abstract][Full Text] [Related]
3. Fine-tuning of intrinsic N-Oct-3 POU domain allostery by regulatory DNA targets.
Alazard R; Mourey L; Ebel C; Konarev PV; Petoukhov MV; Svergun DI; Erard M
Nucleic Acids Res; 2007; 35(13):4420-32. PubMed ID: 17576670
[TBL] [Abstract][Full Text] [Related]
4. Linker length and composition influence the flexibility of Oct-1 DNA binding.
van Leeuwen HC; Strating MJ; Rensen M; de Laat W; van der Vliet PC
EMBO J; 1997 Apr; 16(8):2043-53. PubMed ID: 9155030
[TBL] [Abstract][Full Text] [Related]
5. Structure of the Oct-3 POU-homeodomain in solution, as determined by triple resonance heteronuclear multidimensional NMR spectroscopy.
Morita EH; Shirakawa M; Hayashi F; Imagawa M; Kyogoku Y
Protein Sci; 1995 Apr; 4(4):729-39. PubMed ID: 7613470
[TBL] [Abstract][Full Text] [Related]
6. Solution structure of the POU-specific DNA-binding domain of Oct-1.
Dekker N; Cox M; Boelens R; Verrijzer CP; van der Vliet PC; Kaptein R
Nature; 1993 Apr; 362(6423):852-5. PubMed ID: 8479524
[TBL] [Abstract][Full Text] [Related]
7. Identification of an N-terminal transcriptional activation domain within Brn3b/POU4f2.
Martin SE; Mu X; Klein WH
Differentiation; 2005 Feb; 73(1):18-27. PubMed ID: 15733064
[TBL] [Abstract][Full Text] [Related]
8. N-Oct 5 is generated by in vitro proteolysis of the neural POU-domain protein N-Oct 3.
Atanasoski S; Schreiber E; Fontana A; Herr W
Oncogene; 1997 Mar; 14(11):1287-94. PubMed ID: 9178889
[TBL] [Abstract][Full Text] [Related]
9. Conservative Val47 residue of POU homeodomain: role in DNA recognition.
Stepchenko AG; Luchina NN; Polanovsky OL
FEBS Lett; 1997 Jul; 412(1):5-8. PubMed ID: 9257679
[TBL] [Abstract][Full Text] [Related]
10. [The progress in complex homeobox domains].
Zhou SX; Sun X; Lu ZH
Yi Chuan; 2004 Nov; 26(6):984-90. PubMed ID: 15640136
[TBL] [Abstract][Full Text] [Related]
11. Protein interaction surface of the POU transcription factor UNC-86 selectively used in touch neurons.
Röhrig S; Röckelein I; Donhauser R; Baumeister R
EMBO J; 2000 Jul; 19(14):3694-703. PubMed ID: 10899123
[TBL] [Abstract][Full Text] [Related]
12. Exon 4-encoded acidic domain in the epithelium-restricted Ets factor, ESX, confers potent transactivating capacity and binds to TATA-binding protein (TBP).
Chang CH; Scott GK; Baldwin MA; Benz CC
Oncogene; 1999 Jun; 18(25):3682-95. PubMed ID: 10391676
[TBL] [Abstract][Full Text] [Related]
13. Developmental effects of ectopic expression of the glucocorticoid receptor DNA binding domain are alleviated by an amino acid substitution that interferes with homeodomain binding.
Wang JM; Préfontaine GG; Lemieux ME; Pope L; Akimenko MA; Haché RJ
Mol Cell Biol; 1999 Oct; 19(10):7106-22. PubMed ID: 10490647
[TBL] [Abstract][Full Text] [Related]
14. Solution structure of a POU-specific homeodomain: 3D-NMR studies of human B-cell transcription factor Oct-2.
Sivaraja M; Botfield MC; Mueller M; Jancso A; Weiss MA
Biochemistry; 1994 Aug; 33(33):9845-55. PubMed ID: 7914745
[TBL] [Abstract][Full Text] [Related]
15. The B cell coactivator Bob1 shows DNA sequence-dependent complex formation with Oct-1/Oct-2 factors, leading to differential promoter activation.
Gstaiger M; Georgiev O; van Leeuwen H; van der Vliet P; Schaffner W
EMBO J; 1996 Jun; 15(11):2781-90. PubMed ID: 8654375
[TBL] [Abstract][Full Text] [Related]
16. Identification of linker regions and domain borders of the transcription activator protein NtrC from Escherichia coli by limited proteolysis, in-gel digestion, and mass spectrometry.
Bantscheff M; Weiss V; Glocker MO
Biochemistry; 1999 Aug; 38(34):11012-20. PubMed ID: 10460156
[TBL] [Abstract][Full Text] [Related]
17. Sequence-specific deoxyribonucleic acid (DNA) recognition by steroidogenic factor 1: a helix at the carboxy terminus of the DNA binding domain is necessary for complex stability.
Little TH; Zhang Y; Matulis CK; Weck J; Zhang Z; Ramachandran A; Mayo KE; Radhakrishnan I
Mol Endocrinol; 2006 Apr; 20(4):831-43. PubMed ID: 16339274
[TBL] [Abstract][Full Text] [Related]
18. Functional interaction of the c-Myc transactivation domain with the TATA binding protein: evidence for an induced fit model of transactivation domain folding.
McEwan IJ; Dahlman-Wright K; Ford J; Wright AP
Biochemistry; 1996 Jul; 35(29):9584-93. PubMed ID: 8755740
[TBL] [Abstract][Full Text] [Related]
19. In silico studies of the interaction between BRN2 protein and MORE DNA.
do Vale Coelho IE; Arruda DC; Taranto AG
J Mol Model; 2016 Sep; 22(9):228. PubMed ID: 27568376
[TBL] [Abstract][Full Text] [Related]
20. Characteristic patterns of N Oct-3 binding to a set of neuronal promoters.
Blaud M; Vossen C; Joseph G; Alazard R; Erard M; Nieto L
J Mol Biol; 2004 Jun; 339(5):1049-58. PubMed ID: 15178247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
